Posted by Michael Wonder on 16 Jan 2020
NICE ‘OK’ for Lynparza
16 January 2020 - NICE has recommended MSD and AstraZeneca’s Lynparza (olaparib) tablets, for adults who have relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer with a BRCA1 or BRCA2 mutation.
The decision was based on a clinical trial in which the drug stalled growth of the cancer for around 13.6 months compared to placebo.
The news means that the first-in-class PARP inhibitor is now recommended for routine use in the NHS for people who have had three or more courses of platinum-based chemotherapy, with an estimated 100 people eligible for the treatment through routine commissioning.
